|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's range||15.67 - 16.74|
|52-week range||12.90 - 39.12|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||37.19|
After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM), Intellia Therapeutics (NASDAQ: NTLA), and Schrödinger (NASDAQ: SDGR).
Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.